Результаты поиска

Grzybowski's Generalized Eruptive Keratoacanthomas in a Patient with Terminal Kidney Disease-An Unmet Medical Need Equally Ameliorated by Topical Imiquimod Cream and Lapacho Tea Wraps: A Case Report.

IntroductionDevelopment of singular keratoacanthoma (KA) is generally considered a benign condition as it has a tendency to regress spontaneously in spite of histological similarity to squamous cell carcinoma. Most KAs undergo excision to rule out differential diagnoses. Several alternative treatment modalities (keratinolytic, ablative, immunomodulating, antiproliferative, or targeted therapy) have been described in the past with varying success, underlining the therapeutic challenges associated with large or multiple lesions. Isomorphic response (Koebner phenomenon) may limit the efficacy of

Совпадение в полном тексте источника
… The patient had a high cardiovascular risk factor burden and suffered from arterial hypertension, hyperuricemia, coronary heart disease, and terminal kidney disease due to idiopathic nephropathy. …

Prevalence and characteristics of concomitant septic and crystal-induced arthritis: A hospital database and literature review.

BACKGROUND AND OBJECTIVES: Concomitant septic and crystal-induced arthritis is a rare condition. Failure to diagnose this condition can result in significant harm to the patient. This study aims to investigate the prevalence and characteristics of concomitant septic and crystal-induced arthritis. METHODS: A retrospective study included patients diagnosed with concomitant septic and crystal-induced arthritis confirmed by positive bacterial culture and intracellular crystals in synovial fluid of the same joint, from January 1, 2015, to July 31 ,2024. RESULTS: A total of 45 cases were defined a

Совпадение в полном тексте источника
… Contemporary Prevalence of Gout and Hyperuricemia in the United States and Decadal Trends: The National Health and Nutrition Examination Survey, 2007–2016. Arthritis Rheumatol. 2019;71:991. doi: 10.1002/art.40807. et al . –. [2] Dehlin M, Jacobsson L, Roddy E. …

Guidelines for treatment of renal injury during cancer chemotherapy 2016.

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.

Наркотики, основанные на сходстве генных экспрессионных сигнатур, чтобы исследовать потенциальные признаки кексетина: тематическое исследование множественных склерозов.

Quercetin (QR) — природный флавонол, широко распространенный в королевстве растений с обширными фармакологическими последствиями. Чтобы найти потенциальные клинические показатели QR, 156 Дифференциально выраженные гены (DEG), регулируемые QR, были получены из базы данных Gene Express Omnibus, и новые потенциальные фармакологические эффекты и клинические показатели QR были перенаправлены путем интегрирования соединений с аналогичными генными сигнатурами возмущения и соответствующими сигнатурами болезни QR на основе карты связи и платформ Coexedia. Предлагаемые результаты QR оказывают главным об

Совпадение в полном тексте источника
… Presently, some clinical trials of QR in treating different diseases have been carried out or completed, including rheumatoid arthritis ( Javadi et al., 2017 ), hyperuricemia ( Shi and Williamson, 2016 ), COVID-19 (ongoing clinical trial ID: QUERCOV), chronic obstructive pulmonary disease (ongoing clinical …

CAR T-cell therapy and critical care : A survival guide for medical emergency teams.

Chimeric antigen receptor (CAR) T‑cells are genetically engineered to give T‑cells the ability to attack specific cancer cells, and to improve outcome of patients with refractory/relapsed aggressive B‑cell malignancies. To date, several CAR T‑cell products are approved and additional products with similar indication or extended to other malignancies are currently being evaluated. Side effects of CAR T‑cell treatment are potentially severe or even life-threatening immune-related toxicities, specifically cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (

Совпадение в полном тексте источника
… Tumor lysis syndrome can usually be distinguished by typical laboratory findings, such as hyperuricemia, hyperkalemia, hypocalcemia, and hyperphosphatemia [ 36 ]; however, tumor lysis syndrome and CRS may occur coincidentally [ 37 ]. …

Multiple Myeloma: Cast Nephropathy, VTE, and Neurologic Complications.

Multiple myeloma accounts for approximately 1% of neoplastic diseases and 13% of hematologic cancers. Complications often associated with MM include neurologic and hematologic issues, infections, renal insufficiency, and bone involvement. It is crucial for advanced practice professionals caring for myeloma patients to assess patients accurately, be keenly aware of possible associated complications, and be familiar with appropriate interventions to prevent further injury. This article will provide an overview of MM-related renal insufficiency, with a focus on cast nephropathy, venous thromboemb

Совпадение в полном тексте источника
… According to Tariman (2010), poor hydration and volume depletion; urinary tract infection and sepsis; nephrotoxins such as certain antibiotics, nonsteroidal anti-inflammatory drugs (NSAIDs), IV contrast dyes, and bisphosphonates; hypercalcemia and nephrocalcinosis; and hyperuricemia and urate nephropathy …

Daratumumab in patients with immune thrombocytopenia: a single-center, open-label, phase 2 trial.

BACKGROUND: Immune thrombocytopenia is an autoimmune bleeding disorder. Daratumumab, a human monoclonal antibody targeting CD38 glycoprotein, is currently under clinical investigation as a potential therapy for autoimmune diseases. This trial aimed to evaluate the efficacy and safety of daratumumab in adults with immune thrombocytopenia. METHODS: This single-center, open-label, phase 2 trial enrolled patients with a platelet count <30 × 109 platelets per L during the screening period. The study protocol comprised a 4-week screening phase, an 8-week treatment course, and a 16-week follow-up pe

Совпадение в полном тексте источника
… decreased | 4 (6.3) | 4 (6.3) | 0 | 0 | 0 Increased alanine aminotransferase | 5 (7.9) | 5 (7.9) | 0 | 0 | 0 Increased aspartate aminotransferase | 4 (6.3) | 4 (6.3) | 0 | 0 | 0 Increased γ-glutamyltransferasev | 2 (3.2) | 2 (3.2) | 0 | 0 | 0 Increased alkaline phosphatase | 2 (3.2) | 2 (3.2) | 0 | 0 | 0 Hyperuricemia …

The Use of Extracorporeal Organ Support Therapies for Acute Kidney Injury in Cancer Patients.

Acute kidney injury (AKI) is a frequent and serious complication in patients with cancer, associated not only with increased morbidity and mortality, but also with the interruption or modification of anticancer therapy. In critically ill patients with cancer, AKI arises from a complex interplay of cancer-related, treatment-related, and patient-related factors, with many patients requiring renal replacement therapy (RRT) and admission to the intensive care unit (ICU). This narrative review summarizes the etiology of AKI in patients with cancer and discusses the role of extracorporeal organ supp

Совпадение в полном тексте источника
… Characteristic biochemical features include hyperuricemia, hypocalcemia, hyperphosphatemia, and hyperkalemia. AKI occurs in approximately two-thirds of patients with TLS and is associated with worse outcomes [ 8 ]. …

Low-, moderate-, and high-risk obesity in association with cost drivers, costs over the lifecycle, and life expectancy.

BackgroundThe prevalence of low-, moderate-, and high-risk obesity has been increasing globally. Our aim was to estimate the societal burden of these three obesity classes in the Austrian population by taking a societal-annual perspective and an individual-life-cycle perspective. Secondly, we sought to identify the respective cost drivers and the effects on life expectancy.MethodsWe used population-weighted survey data on the distribution of body mass index (BMI) and data on relative risks regarding 83 diseases. Using fractional polynomial regressions, we estimated relative risks per BMI unit

Совпадение в полном тексте источника
… The selection also included pregnancy and birth complications and health consequences for children but excluded any obesity-related disease severities, complications, or disease recurrences as well as preliminary stages of diseases such as dyslipidemia, hyperuricemia, and prediabetes/insulin resistance …

Daratumumumab, Bortezomib и Dexamethasone для лечения пациентов с повторной или рефрактной множественной миеломой и тяжелыми реанимациями: результаты фазы 2 Испытание GMG-DANTE.

Деформация функции real (RI) — обычное осложнение в множестве миеломы (MM). Вместе с тем имеются ограниченные данные о безопасности и эффективности антиММ-режимов у пациентов с тяжелым RI, поскольку эти пациенты часто исключаются из клинических испытаний. Этот эксперимент, инициированный следователем по многоцентрическому этапу II GMG-DANTE, позволил оценить даратумумаб, бортезомиб и дексаметасон (DVd) в случае рецидива или рецидива (r/r) пациентов MM с тяжелыми пациентами RI. r/RMM ≥1 предыдущая линия обработки и ГФР <30 мл/мин.1.73 m2 или гемодиализ имели право на получение eight циклы DVd,

Совпадение в полном тексте источника
… 38.1) Prior treatment lines –median (range) | 2 (1–10) Prior bortezomib exposure – n (%) | 20 (95.2) Prior lenalidomide exposure – n (%) | 9 (42.9) Prior stem cell transplantation – n (%) | 6 (28.6) Comorbidities n (%) c | Arterial hypertension | 9 (42.9) Diabetes mellitus | 4 (19.0) Anemia | 4 (19.0) Hyperuricemia …

Approaches to Managing Safety With Lenalidomide in Hematologic Malignancies.

Lenalidomide is an oral immunomodulatory agent approved in relapsed multiple myeloma with dexamethasone, for transfusion-dependent anemia in myelodysplastic syndrome associated with deletion 5q, and in relapsed/progressive mantle cell lymphoma following bortezomib. In recent clinical trials, lenalidomide has shown promising activity in hematologic malignancies, including chronic lymphocytic leukemia (CLL) and non-Hodgkin lymphoma (NHL). Starting doses and dosing schedules vary by malignancy, with lenalidomide started at a lower dose for CLL than for NHL or multiple myeloma. Certain adverse eve

Совпадение в полном тексте источника
… Symptoms include hyperuricemia, hyperkalemia, hyperphosphatemia, hypocalcemia, cardiac arrhythmia, and uremia, which may lead to renal dysfunction and potentially acute renal failure. …

Immunotherapy in chronic lymphocytic leukemia: advances and challenges.

Chronic lymphocytic leukemia (CLL) is characterized as a clonal proliferation of mature B lymphocytes with distinct immunophenotypic traits, predominantly affecting the middle-aged and elderly population. This condition is marked by an accumulation of lymphocytes within the peripheral blood, bone marrow, spleen, and lymph nodes. The associated immune dysregulation predisposes CLL patients to a higher risk of secondary malignancies and infections, which significantly contribute to morbidity and mortality rates. The advent of immunotherapy has revolutionized the prognosis of CLL, advancing treat

Совпадение в полном тексте источника
… In more severe cases, rapid cell lysis induced by CD20 mAbs can result in tumor lysis syndrome (TLS), a condition that may lead to complications such as hyperkalemia and hyperuricemia [ 58 ]. The incidence of TLS is relatively low, estimated at from 1–5% [ 59 ]. … This can cause significant metabolic disturbances, including hyperkalemia, hyperphosphatemia, and hyperuricemia, which may lead to acute kidney injury and other severe complications. …

Diagnosis and treatment of Paget's disease of bone: position paper from the Italian Society of Osteoporosis, Mineral Metabolism and Skeletal Diseases (SIOMMMS).

INTRODUCTION: Paget's disease of bone is a focal skeletal disorder causing bone deformities and impairing bone quality. Despite the prevalence of asymptomatic cases is increasing, the progression of the disease can lead to invalidating complications that compromise the quality of life. Doubts on clinical and therapeutic management aspects exist, although beneficial effects of antiresorptive drugs, particularly bisphosphonates are known. However, limited information is available from randomized controlled trials on the prevention of disease complications so that somewhat contrasting positions a

Совпадение в полном тексте источника
… Osteoarthritis at adjacent joints Pseudo-fractures and fractures Neurological Headache Hearing loss Cranial nerve deficits Tinnitus Basilar invagination Obstructive hydrocephalus Paraplegia, paraparesis Dementia (vascular steal syndrome) Metabolic Hyperparathyroidism* Nephrolithiasis Hypercalcemia Hyperuricemia … fractures | | Neurological | Headache | Hearing loss | Cranial nerve deficits | | Tinnitus | Basilar invagination | | | Obstructive hydrocephalus | | | Paraplegia, paraparesis | | | Dementia (vascular steal syndrome) Metabolic | Hyperparathyroidism* | Nephrolithiasis | Hypercalcemia | | | Hyperuricemia …

Drug repurposing for disease-modifying effects in multiple system atrophy.

Multiple system atrophy (MSA) is a rapidly progressive neurodegenerative disorder lacking any proven disease-modifying therapy. Drug repurposing offers a strategy to accelerate the development of treatments by utilizing agents originally approved for other indications. This review summarizes repurposed drugs investigated as disease-modifying therapies for MSA, spanning preclinical in vitro and animal studies and clinical trials. We focus on agents targeting key pathogenic mechanisms in MSA-including α-synuclein aggregation (e.g., sirolimus/rapamycin, rifampicin, lithium, nilotinib, epigallocat

Совпадение в полном тексте источника
… uric acid, reduces α-syn spread and neurodegeneration; higher serum urate correlates with slower MSA progression (observational) | Phase II trial (IMPROVE-MSA, 24 weeks): inosine monophosphate safely raised serum uric acid (~ 4.6 to 7.0 mg/dL) vs. placebo; well tolerated (few cases of asymptomatic hyperuricemia … Three IMP recipients developed asymptomatic hyperuricemia (UA ≥ 9 mg/dL), all managed by dose reduction/temporary hold; no gout occurred. Serious AEs were similar (20.0% in the treatment group vs. 16.0% in the placebo group), with deaths of 1 vs. 2, none attributed to the study drug. …

Статинское воздействие после многократного диагностирования миеломы и риск полной смертности, венозного тромбоэмболизма, патологических переломов и острых повреждений почек: ретроспективное когортное исследование.

Множественная миелома (ММ) сопряжена со значительным риском венозного тромбоэмболизма (VTE), патологических переломов, острых повреждений почек (AKI) и смерти. Статины обладают антивоспалительными, иммунодуляционными и антитромботическими свойствами, которые могут уменьшить эти осложнения, однако их связи с рядом ключевых результатов MM не оценивались одновременно в одной реальной группе. ЦЕЛИ: Оценить связь между воздействием последиагностической статистики и 5-year Смертельная смертность, VTE, патологические переломы и AKI в MM. МЕТОДЫ: Мы провели ретроспективное когортное исследование в сет

Совпадение в полном тексте источника
… ) | 15 548 (45.4) | <0.001 | 0.143 | 3753 (52.4) | 3813 (53.2) | 0.315 | 0.017 Mixed hyperlipidemia | 1839 (21.0) | 7227 (21.1) | 0.863 | 0.002 | 1514 (21.1) | 1544 (21.5) | 0.541 | 0.010 Overweight and obesity | 2759 (31.5) | 9896 (28.9) | <0.001 | 0.057 | 2214 (30.9) | 2232 (31.1) | 0.745 | 0.005 Hyperuricemia …

Efficacy, safety, and pharmacokinetics of teclistamab in Chinese patients with relapsed/refractory multiple myeloma from the China cohort of MajesTEC-1.

IntroductionTeclistamab, the first approved B-cell maturation antigen-directed bispecific antibody for treatment of triple-class exposed relapsed/refractory multiple myeloma, demonstrated deep, durable responses with a manageable safety profile in the pivotal MajesTEC-1 cohort (NCT03145181/NCT04557098). Efficacy, safety, and pharmacokinetics from the MajesTEC-1 China cohort are reported.MethodsPatients received teclistamab 1.5 mg/kg subcutaneously weekly after step-up dosing; patients could switch to less frequent dosing with continued response.ResultsIn the China cohort (N = 26; median age, 6

Совпадение в полном тексте источника
… | 8 (30.8) | 0 | 0 Aspartate aminotransferase increased | 8 (30.8) | 0 | 0 Hyponatremia | 7 (26.9) | 2 (7.7) | 0 Constipation | 7 (26.9) | 0 | 0 Cough | 7 (26.9) | 0 | 0 Headache | 7 (26.9) | 0 | 0 Hyperglycemia | 6 (23.1) | 3 (11.5) | 0 Gamma‐ glutamyltransferase increased | 6 (23.1) | 1 (3.8) | 0 Hyperuricemia …

Proteomic analysis of plasma proteins of high-flux haemodialysis and on-line haemodiafiltration patients reveals differences in transthyretin levels related with anaemia.

A large proportion of end-stage renal disease (ESRD) patients under long-term haemodialysis, have persistent anaemia and require high doses of recombinant human erythropoietin (rhEPO). However, the underlying mechanisms of renal anaemia have not been fully elucidated in these patients. In this study, we will be focusing on anaemia and plasma proteins in ESRD patients on high-flux haemodialysis (HF) and on-line haemodiafiltration (HDF), to investigate using two proteomic approaches if patients undergoing these treatments develop differences in their plasma protein composition and how this could

Совпадение в полном тексте источника
… Interestingly, HF patients had hyperuricemia (8.73 ± 0.47 mg/dL uric acid, > 6.8 mg/dL), whereas HDF patients had lower uric acid levels (6.78 ± 0.37 mg/dL), being this difference significant ( p = 0.0075) (Table 1 ). …

Activin Receptor-Ligand Trap for the Treatment of β-thalassemia: A Serendipitous Discovery.

β-thalassemia is a hereditary disorder caused by defective production of β-globin chains of hemoglobin (Hb) that leads to an increased α/β globins ratio with subsequent free α-globins. Alpha globin excess causes oxidative stress, red blood cells membrane damage, premature death of late-stage erythroid precursors, resulting in ineffective erythropoiesis. The transforming growth factor β (TGF-β) superfamily signaling acts on biological processes, such as cell quiescence, apoptosis, proliferation, differentiation, and migration, and plays an essential role in regulating the hematopoiesis. This pa

Совпадение в полном тексте источника
… Adverse events of transient bone pain, arthralgia, dizziness, hypertension, and hyperuricemia were more frequent with luspatercept than placebo. 46 A 5-year open-label extension phase is ongoing to provide long-term efficacy and safety data. …

Joint manifestations revealing inborn metabolic diseases in adults: a narrative review.

Inborn metabolic diseases (IMD) are rare conditions that can be diagnosed during adulthood. Patients with IMD may have joint symptoms and the challenge is to establish an early diagnosis in order to institute appropriate treatment and prevent irreversible damage. This review describes the joint manifestations of IMD that may be encountered in adults. The clinical settings considered were arthralgia and joint stiffness as well as arthritis. Unspecific arthralgias are often the first symptoms of hereditary hemochromatosis, chronic low back pain may reveal an intervertebral disc calcification in

Совпадение в полном тексте источника
… The biological profile includes hyperuricemia (usually greater than patients with primary gout) with hyperuricosuria. Diagnosis is made by measuring the activity of the enzyme on erythrocytes and fibroblasts in culture [ 44 ]. …

Selinexor plus ruxolitinib in JAK inhibitor-naïve patients with myelofibrosis: a multicenter, open-label, phase 1 study.

AbstractThe phase 1 portion of SENTRY/XPORT-MF-034 (NCT04562389) evaluated the exportin 1 inhibitor selinexor (40 mg/60 mg once weekly) plus ruxolitinib in JAK inhibitor-naïve patients with myelofibrosis (n = 24). Primary end points were maximum tolerated selinexor dose, recommended clinical trial dose, and safety. No dose-limiting toxicities were reported. Common adverse events were nausea, fatigue, anemia, thrombocytopenia, constipation, vomiting, and headache. Nausea was transient, mainly grade 1, and managed by prophylactic antiemetics. Four deaths occurred, all unrelated to study treatmen

Совпадение в полном тексте источника
… Cardiac failure | 1 (10) | 0 | 1 (4) Chest pain | 0 | 1 (7) | 1 (4) Death | 0 | 1 (7) | 1 (4) Decreased appetite | 0 | 1 (7) | 1 (4) Delirium | 0 | 1 (7) | 1 (4) Dizziness | 1 (10) | 0 | 1 (4) Dysphagia | 0 | 1 (7) | 1 (4) Failure to thrive | 0 | 1 (7) | 1 (4) Febrile neutropenia | 0 | 1 (7) | 1 (4) Hyperuricemia …